Outcomes of Drug Coated Balloon Angioplasty, A UK Real Life Experience From 2009 to 2015
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Ischaemic Heart Disease
- Sponsor
- Julie Dawson
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- Target Vessel Revascularisation (TVR)
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
This is a single center, retrospective, observational cohort study to assess the safety and efficacy of drug coated balloon (DCB) angioplasty in all forms of coronary artery disease. The Investigators intend to report outcomes of all patients who received DCB angioplasty at their center during the above mentioned period for up to 10 years.
Detailed Description
The Investigators expect to assess outcomes of all patients who received Drug Coated Balloon Angioplasty treatment, which is a novel therapy as opposed to standard Drug Eluting Stent insertion, for all types of coronary artery disease from 01/01/2009 till 31/12/2015 in their center. The Investigators believe the number exceeds 1000 patients. The Investigators plan to collect demographic and procedural data from their existing data base. They will request up to date follow-up events from NICOR (National Institute for Cardiovascular Outcomes Research, UK) in 2017(data ending December 2016), by which time all patientswould have had minimum of 12 months follow up. The Investigators plan to incorporate these findings to their data set and report the comprehensive outcomes. Primary end point will be major adverse cardiac outcomes (MACE) defined as a composite of death, myocardial infarction and target vessel revascularisation. Secondary end points will be acute vessel closure and target lesion revascularisation. The Investigators also have a long term plan of requesting follow-up events from NICOR for up to 10 years, so they can report on long term outcomes of drug coated balloon treatment.
Investigators
Julie Dawson
Research Services Manager
Norfolk and Norwich University Hospitals NHS Foundation Trust
Eligibility Criteria
Inclusion Criteria
- •All patients who were treated with drug coated balloon angioplasty during 01/01/2009 - 31/12/2015 at Norfolk and Norwich University Hospital.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Target Vessel Revascularisation (TVR)
Time Frame: 12 months and then up to 10 years
A TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The latter is defined as the entire major coronary vessel proximal and distal to the target lesion, including upstream and downstream branches and the target lesion itself.
Major adverse cardiac events (MACE) defined as a composite of all cause death, myocardial infarction and target vessel revascularisation for 12 months and then up to 10 years
Time Frame: 12 months and then up to 10 years
Death. All cause death will be defined as death due to any cause. . Target vessel revascularisation (TVR) A TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The latter is defined as the entire major coronary vessel proximal and distal to the target lesion, including upstream and downstream branches and the target lesion itself.
Myocardial Infarction (MI)
Time Frame: 12 months and then up 10 years
An MI is defined as an episode of chest pain with positive cardiac enzyme troponin as per MINAP definition (a hospital diagnosis reported as a troponin positive MI).
Secondary Outcomes
- Acute vessel closure and target lesion revascularisation for 12 months and then up to 10 years.(12 months and then up to 10 years)
- TLR(12 months and then up to 10 years)